Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Validation of biomarkers associated with the risk of developing diabetes as well as accelerated weight and lung function loss in a multinational prospective cystic fibrosis cohort
FY 2015-16
Summary
Cystic fibrosis (CF) is the most common fatal recessive genetic disease in Canada. Increased longevity due to aggressive treatments is however associated with the emergence of new complications, including cystic fibrosis-related diabetes (CFRD), with a prevalence of above 50% in patients over 30 years. CFRD is associated with a decline in weight and in pulmonary function, increasing the risk of morbidity and mortality. In order to target patients needing more intensive monitoring and interventions, it is important to establish biomarkers that could predict the risk of CFRD and also the risk of accelerated clinical deterioration. Our hypotheses are that postprandial hyperglycemia and/or hypoinsulinemia play a causal role in the accelerated clinical deterioration preceding and accompanying the onset of CFRD. We also propose that 1-h values of the oral glucose tolerance test (OGTT) are more sensitive markers than the 2-h values normally used. We have data supporting our hypotheses. Our first goal is to validate, over 4 years, blood glucose and insulin values at 1-h during an OGTT as biomarkers of increased risk of 1) developing CFRD, 2) accelerated decline in lung function and 3) accelerated weight loss. However, to achieve the required statistical power, a larger sample than ours, based in Montreal (280 CF patients), is needed. To succeed, we will pool our data with a similar ongoing cohort that was established in 2010 in Lyon (France, Rhône-Alpes cohort), which includes more than 120 patients. These two cohorts will provide the largest CF cohort to study the risk of CFRD and relations between blood sugar and insulin levels as well as between lung function and weight.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350152
Name
Boudreau Valérie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validation of biomarkers associated with the risk of developing diabetes as well as accelerated weight and lung function loss in a multinational prospective cystic fibrosis cohort
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
1-H Oral Glucose Tolerance Test; Biomarkers; Cystic Fibrosis; Diabetes; Hyperglycemia; Hypoinsulinemia; Multinational Cohort; Pancreatic Fibrosis; Pulmonary Function; Weight
Abstract
Cystic fibrosis (CF) is the most common fatal recessive genetic disease in Canada. Increased longevity due to aggressive treatments is however associated with the emergence of new complications, including cystic fibrosis-related diabetes (CFRD), with a prevalence of above 50% in patients over 30 years. CFRD is associated with a decline in weight and in pulmonary function, increasing the risk of morbidity and mortality. In order to target patients needing more intensive monitoring and interventions, it is important to establish biomarkers that could predict the risk of CFRD and also the risk of accelerated clinical deterioration. Our hypotheses are that postprandial hyperglycemia and/or hypoinsulinemia play a causal role in the accelerated clinical deterioration preceding and accompanying the onset of CFRD. We also propose that 1-h values of the oral glucose tolerance test (OGTT) are more sensitive markers than the 2-h values normally used. We have data supporting our hypotheses. Our first goal is to validate, over 4 years, blood glucose and insulin values at 1-h during an OGTT as biomarkers of increased risk of 1) developing CFRD, 2) accelerated decline in lung function and 3) accelerated weight loss. However, to achieve the required statistical power, a larger sample than ours, based in Montreal (280 CF patients), is needed. To succeed, we will pool our data with a similar ongoing cohort that was established in 2010 in Lyon (France, Rhône-Alpes cohort), which includes more than 120 patients. These two cohorts will provide the largest CF cohort to study the risk of CFRD and relations between blood sugar and insulin levels as well as between lung function and weight.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boudreau, Valérie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~